Introduction
============

The morbidity and mortality rate of cardiovascular disease (CVD) is relatively high worldwild [@B1]. Cellular senescence is an irreversible arrest of cell growth. Accumulating evidence suggests that cellular senescence exerts important effects on vascular endothelial dysfunction, which is believed to be an early pathological event during CVD development. For example, secretion of atherosclerosis-related factors, such as intercellular adhesion molecule-1 and the inhibitory activity of endothelial nitric oxide synthase, is found in senescent human umbilical vein endothelial cells (HUVECs) [@B2]. Atrial endothelial senescence was found to promote thrombus formation and extracellular matrix remodeling [@B3]. In an aging mouse model with vascular endothelium damage, antioxidant therapy can alleviated the dysfunction of aging vascular endothelium cells [@B4]. Studies have shown that long-term addition of the antioxidant vitamin C (VC), which can reduce the immune levels associated with thymic aging [@B5]. VC may also be involved in the function of cardiovascular endothelial cells [@B6], which can improve endothelial dysfunction in patients with hypertension [@B7]. However, the mechanisms of VC in cardiovascular aging-related endothelial injury are still unclear.

Piwi-interacting RNAs (piRNA) are a type of non-coding RNA of approximately 26-32 nucleotides in length [@B8]. They maintain genomic integrity by regulating the expression of retrotransposons [@B9], [@B10]. piRNA is widely expressed in adult cells, including germ cells, cardiomyocytes, and cerebral vascular endothelial cells, and it is involved in regulating CVD-related pathways [@B11]-[@B14]. However, the expression pattern of piRNA in the context of cardiovascular endothelial cell senescence remains unknown.

Herein, we investigated the effect of VC on H~2~O~2~-induced senescence in endothelial cells and whether piRNA is involved in VC-mediated antiaging effects.

Materials and Methods
=====================

Cell culture and drug treatment
-------------------------------

HUVEC (PUMC-HUVEC-T1) were purchased from the Cell Resource Center of IBMS, CAMS/PUMC (Beijing, China). Cells were cultured in Dulbecco\'s Modified Eagle\'s Medium (DMEM; Invitrogen, Waltham, MA, USA) containing 10% fetal bovine serum and incubated in a 5% CO~2~ incubator at 37°C. Cells were treated with H~2~O~2~ (100 μM) to create an *in vitro* model of senescence (H~2~O~2~ group) [@B15]-[@B17]. After 2 h, some of these cells were then cultured in medium containing VC (200 μM; Sigma-Aldrich, St. Louis, MO, USA) to investigate the effect of VC on aging endothelial cells (VC group). Cells without H~2~O~2~ or VC treatment were used as negative controls (Control group).

Flow cytometry
--------------

Approximately 10^6^ cells for each treatment condition were collected and suspended in cold PBS. Cells were then incubated in 70% ethanol overnight. The following day, cells were incubated in propidium iodide (BD Biosciences, San Jose, CA, USA) and subjected to flow cytometry (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) to determine the stages of cell cycle. DNA content was calculated at each phase of the cell cycle.

\[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium\] (MTS) assay
--------------------------------------------------------------------------------------------------------

Cells were grown in a 96-well-plate at a density of 1×10^4^/well and incubated in 10% DMEM containing 20 μL of Cell Titer 96 AQueous One Solution Reagent (Promega, Madison, WI, USA). Following incubation for 1 h, cell viability was assessed by determining absorbance at 450 nm using a 96-well plate reader (Bio-Rad Laboratories, Hercules, CA, USA).

Western blot analysis
---------------------

To explore the effect of VC on HUVECs senescence, the expression of p16, a marker of cellular senescence [@B18]-[@B20] was detected by Western blot analysis. After H~2~O~2~ and VC treatment, cells were harvested and lysed using RIPA buffer (Beyotime Biotechnology, Shanghai, China). Proteins were quantified using a Bradford assay kit (Pierce, Rockford, IL, USA) and were resolved on a 10% SDS-polyacrylamide gradient gel by electrophoresis. Proteins were then transferred to polyvinylidene fluoride membranes (Millipore, Burlington, MA, USA). The membranes were incubated in 5% bovine serum albumin for 1 h. To detect p16 expression, anti-p16 antibody (10883-1-AP, Proteintech, Rosemont, IL, USA, diluted 1:1000) was added to the membranes and incubated at 4°C overnight. Then, the membranes were incubated with secondary HRP-conjugated antibody (ab6721, Abcam, Cambridge, MA, USA, diluted 1:2000) at room temperature for 1 h. Horseradish peroxidase (HRP) signal was detected using a chemiluminescence reagent (Millipore, Burlington, MA, USA). Protein expression was quantified using ImageJ software (version 1.8.0, National Institutes of Health, Bethesda, MD, USA). GADPH (Abcam, Cambridge, MA, USA) was used as the internal control.

RNA sequencing
--------------

TRizol reagent (Thermo Scientific, Waltham, MA, USA) was used to isolate total RNA from the cells. Small RNA libraries were generated using the TruSeq small RNA library preparation kit (Illumina, San Diego, CA, USA) according to the manufacturer\'s recommendation. RNA sequencing was performed on an Illumina HiSeq 2000 platform (Illumina, San Diego, CA, USA) for small RNA sequencing. Cutadapt (version 1.8.1, National Bioinformatics Infrastructure Sweden, Uppsala, Sweden) were used to remove low-quality reads (sequences containing the linker, \>10% N bases, or \>50% bases with a \<10 mass value) from resulting raw data, the remaining sequences were further aligned against the human genome (hg19). Reads that were between 26 and 32 nucleotides in length met the criteria for piRNAs [@B8].

Bioinformatics analysis
-----------------------

An R package (version 3.1, Lucent Technologies, Reston, VA, USA) was used to analyze the differentially expressed piRNAs. piRNAs that were differentially expressed following H~2~O~2~ treatment with or without VC were defined using a fold change of \> 2 and Benjamini-Hochberg false discovery rate of \< 0.001. An R package was used to predict candidate target mRNA for the piRNAs that were ranked in the top 10 for fold change and were restored by VC. Candidate mRNA and piRNA interaction networks were drawn using Cytoscape software (version 3.7.2, Cytoscape Consortium, San Diego, CA, USA).

To predict the function of the piRNAs involved in the effect of VC, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment (<https://www.genome.jp/kegg/>) and Gene Ontology (GO) analysis (<http://geneontology.org/>) were performed using an R package according to accepted standards.

Statistical analysis
--------------------

Data were expressed as mean ± standard deviation. Statistical analysis were performed using SPSS software (version 10.0, International Business Machines Corporation, Armonk, NY, USA). Comparison of differences between groups was performed using one-way analysis of variance with Fisher LSD post-hoc tests. A *p* value of \< 0.05 was considered significant.

Results
=======

VC alleviates H~2~O~2~-mediated endothelial cell senescence
-----------------------------------------------------------

Flow cytometry analysis showed that, compared with the control group, H~2~O~2~ treatment increased the proportion of the cells in G1 phase, resulting in a decrease in the proportion of cells in the S phase and G2/M phase. Conversely, VC treatment in H~2~O~2~-exposed cells significantly increased the proportion of cells in the S phase and G2/M phase (Fig. [1](#F1){ref-type="fig"}a). MTS assay revealed that, compared with the control group, exposure to H~2~O~2~ (H~2~O~2~ group) for 72 h resulted in a significant decrease in cell viability, whereas cells treated with VC after H~2~O~2~ exposure (VC group) had significantly higher cell viability than the H~2~O~2~ group (Fig. [1](#F1){ref-type="fig"}b). In addition, western blot analysis showed that the expression of p16 was significantly elevated after H~2~O~2~ exposure, and treatment with VC can reduce the expression of p16 induced by H~2~O~2~ exposure (Fig. [1](#F1){ref-type="fig"}c).

piRNA expression profile following VC treatment
-----------------------------------------------

RNA-seq was performed to characterize the piRNA expression in control, H~2~O~2~, and VC groups respectively. As shown in Fig. [2](#F2){ref-type="fig"}a, a volcano plot revealed that many piRNAs were differentially expressed in the H~2~O~2~ group compared with the control group. Of these, 340 piRNAs were upregulated, and 62 piRNAs were downregulated (Fig. [2](#F2){ref-type="fig"}a). The VC group also had significantly different expression levels of many piRNAs (Fig. [2](#F2){ref-type="fig"}b). There were 36 upregulated and 56 downregulated piRNAs in the VC group compared with the H~2~O~2~ group. Unbiased hierarchical clustering analysis showed a sequence of piRNAs that were upregulated after H~2~O~2~ induction and downregulated when VC was added to the cells. Conversely, some piRNAs were downregulated after H~2~O~2~ induction and were restored after VC treatment (Fig. [2](#F2){ref-type="fig"}c).

Potential role of aging-associated and VC-responsive piRNAs
-----------------------------------------------------------

KEGG pathway enrichment analysis was performed using the target genes of differentially expressed piRNAs that were abnormally regulated in the H~2~O~2~ group and restored in the VC group. As shown in Fig. [3](#F3){ref-type="fig"}, KEGG analysis revealed that a series of piRNA target genes were enriched in the cell cycle pathway.

To visualize the regulatory network of piRNAs restored by VC treatment in the cell cycle pathway, two piRNA-mRNA networks, one for the upregulated piRNAs and one for the downregulated piRNAs, were generated. The upregulated piRNA-mRNA network consisted of 36 piRNAs and 73 cell cycle-associated mRNAs (Fig. [4](#F4){ref-type="fig"}a), and the downregulated network consisted of 56 piRNAs and 78 cell cycle-associated mRNAs (Fig. [5](#F5){ref-type="fig"}a). GO analysis of the target genes of these piRNAs revealed that the top two terms within each block were cellular process, single-organism process, cell, cell part, binding, and catalytic activity (Fig. [4](#F4){ref-type="fig"}b and [5](#F5){ref-type="fig"}b).

Discussion
==========

The present study assessed the protective effects of VC in the H~2~O~2~ model of cellular senescence in HUVECs. H~2~O~2~ treatment promoted cell arrest in the G1 phase, inhibited cell proliferation, and increased expression of aging markers. VC treatment attenuated the effects of H~2~O~2~ on cell cycle, cell proliferation, and expression of cell senescence markers. Further analysis of the piRNA expression profiles in the control group, H~2~O~2~ group, and VC group demonstrated that VC can repair the altered piRNA expression profile induced by H~2~O~2~. Moreover, bioinformatics analysis showed that the protective effect of VC on the H~2~O~2~ group is related to the cell cycle.

When cells are stimulated by external factors, they may exhibit protective responses such as apoptosis, autophagy, and aging. Damaged endothelial cells are more likely to age than undamaged cells [@B21]. One of the manifestations of the cellular aging response to stress is G1 arrest. This change in cell cycle inhibits the proliferation of damaged cells and prevents potential malignant cellular transformations. Studies have shown that the decline in yeast cell proliferation caused by aging and cell death is associated with G1/S phase transition disorders [@B22]. Decreased cell proliferation levels and G1 phase cell arrest were also observed in senescent breast cancer cells [@B23]. These studies suggest that the blockade of the G1/S phase transition and decreased cell proliferation levels are among the hallmarks of cellular senescence. In addition to cell cycle transformation disorders, increased expression of the cell senescence marker p16 can be observed [@B23]. Previous studies have suggested that p16 inhibits function of cyclin-dependent kinases, causing G1 cell cycle arrest [@B18]. The current study used the oxidant H~2~O~2~ to observe the effects of VC on cell cycle and cell viability. H~2~O~2~ induced a decrease in endothelial cell viability and inhibition of G1/S transformation, whereas VC treatment ameliorated the senescence-associated profile. These results suggest that VC has a role in alleviating the H~2~O~2~-induced cellular senescence phenotype.

The current study also found that the effect of VC on HUVECs treated with H~2~O~2~ is related to piRNAs. Prior to the present report, only one study demonstrated the presence of piRNAs in prostate epithelial tissue from a vitamin D supplementation trial, suggesting that piRNA expression may be associated with the effects of vitamins [@B24]. The current study provides evidence of piRNA expression related to VC. Furthermore, the functional prediction of piRNA target genes that were normalized following VC treatment revealed that these targets are enriched in numerous signaling pathways including cell cycle, endocytosis, circadian entrainment, Wnt signaling pathway, Forkhead box O (FoxO) signaling pathway, cholinergic synapse, oxytocin signaling pathway, axon guidance, and adrenergic signaling in cardiomyocytes. Among these pathways, the FoxO signaling pathway notably mediates oxidative stress and prolongs lifespan [@B25], [@B26]. The oxytocin signaling pathway may play a role in regulating CVD and age-related disorders [@B27], [@B28]. In particular, cell cycle is a significant pathway that corresponds with the observed improvement of G1/S transition in VC-treated cells. Therefore, we speculate that the function of some piRNAs may associate with the effect of VC in H~2~O~2~-treated cells, while more experimental evidence is needed in future studies.

By constructing the piRNA-mRNA interaction networks, the current study demonstrated that VC-mediated regulation of endothelial function-associated piRNAs regulates a range of cell cycle-related genes. However, the precise function of these differentially expressed piRNAs is still unknown. Among the targets of the piRNAs within the network, *CDK2* is an important gene that regulates the cell cycle and promotes cell cycle transition by binding to different ligands. For example, *CDK2* binding to cyclin E can phosphorylate retinoblastoma protein to promote the G1/S phase transition [@B29], [@B30]. It also has been found that *MDM2* promotes the G1/S transition that is suppressed by p53 [@B31]. Furthermore, *MYC* functions to promote cell cycle progression, and inhibition of *MYC* expression can lead to G1 arrest [@B32], [@B33]. In addition, *HDAC1* is necessary to suppress G1/S phase transitions [@B34]. Finally, *MCM* is a gene that rests during G1, and it is activated after cells enter the S phase. *MCM* plays an important role in the replication of S phase cells [@B35]. Therefore, we propose that the piRNAs dysregulated by H~2~O~2~ were protected by VC treatment, and their association with the cell cycle may facilitate G1/S transition that was suppressed by H~2~O~2~ and may contribute to delays in cellular senescence.

In summary, the current study found that VC plays a role in repairing the H~2~O~2~-induced aging phenotype of vascular endothelial cells and may have a protective effect on aging-related CVD. Furthermore, this VC-induced antiaging phenotype may be related to piRNA expression. These piRNAs were primarily enriched in antiaging, metabolic, and aging-related cardiovascular regulatory pathways. This study supports the hypothesis that piRNAs play a significant role in the effect of VC against endothelial aging.
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![**Effects of VC on H~2~O~2~-induced senescence in endothelial cells.** (a) Flow cytometry showing the DNA content in each phase of the cell cycle, normalized to total content and expressed as a percent of cells in each cell cycle. (b) MTS assay showing the dynamic changes in cell viability 72 h after VC treatment. (c) Quantification of p16 protein expression after VC treatment. Control group, HUVEC cells without any treatment; H~2~O~2~ group, HUVEC cells exposed to H~2~O~2~; VC group, HUVEC cells exposed to H~2~O~2~ followed by treatment with VC. \*\*\*\* *p* \< 0.0001, H~2~O~2~ group vs control group; \#\#\#\# *p* \< 0.0001, VC group vs H~2~O~2~ group.](ijmsv17p0946g001){#F1}

![**Volcano plot (a, b) and hierarchical clustering analysis (c) revealing the differentially expressed piRNAs that were observed after H~2~O~2~ induction and recovery by VC.** Control group, HUVEC cells without any treatment; H~2~O~2~ group, HUVEC cells exposed to H~2~O~2~; VC group, HUVEC cells exposed to H~2~O~2~ followed by treatment with VC.](ijmsv17p0946g002){#F2}

![KEGG enrichment analysis showing signaling pathways related to potential function of differentially expressed piRNA target genes.](ijmsv17p0946g003){#F3}

![**Functional analysis of VC-associated piRNAs.** (a) piRNA-mRNA regulatory network, mRNA were enriched in cell cycle pathway in KEGG analysis, piRNAs of those upregulated by H~2~O~2~ and recovered by VC treatment (b) GO analysis predicting the potential role of piRNA target genes in (a).](ijmsv17p0946g004){#F4}

![**Functional analysis of VC-associated piRNAs.** (a) piRNA-mRNA regulatory network, mRNA were enriched in cell cycle pathway in KEGG analysis, piRNAs were those downregulated by H~2~O~2~ and rescued by VC treatment (b) GO analysis predicting the potential role of piRNA target genes in (a).](ijmsv17p0946g005){#F5}
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